Biofrontera Inc(BFRI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 5:02 PM ET (Korea 10/24 06:02)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.59 | Insider Own | 13.53% | Shs Outstand | 14.2M | Perf Week | -3.96% |
| Market Cap | 0.01B | Forward P/E | 3.95 | EPS next Y | 151.28% | Insider Trans | - | Shs Float | 12.8M | Perf Month | -34.24% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.22 | Inst Own | 19.63% | Short Float | 1.14% | Perf Quarter | -24.85% |
| Income | -0.01B | P/S | 0.25 | EPS this Y | 62.5% | Inst Trans | 4.19% | Short Ratio | 0.27 | Perf Half Y | -26.94% |
| Sales | 0.05B | P/B | 1.88 | EPS next 5Y | - | ROA | -28.8% | Short Interest | 0.15M | Perf YTD | 38.44% |
| Book/sh | 0.42 | P/C | 2.51 | EPS past 3/5Y | -19.6% 44.08% | ROE | -988.35% | 52W High | -52.46% ($1.66) | Perf Year | -30.17% |
| Cash/sh | 0.31 | P/FCF | - | Sales past 3/5Y | 13.3% 17.21% | ROIC | -49.01% | 52W Low | 42.26% ($0.55) | Perf 3Y | -79.5% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 73.13% | Gross Margin | 89.47% | Volatility(W/M) | 4.58% 7.61% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.32 | Sales Y/Y TTM | 17.83% | Oper. Margin | -2.97% | ATR (14) | 0.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.08 | EPS Q/Q | 91.8% | Profit Margin | -13.78% | RSI (14) | 28.56 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.18 | Sales Q/Q | 32.92% | SMA20 | -13.75% ($0.92) | Beta | 0.89 | Target Price | $6 |
| Payout | - | Debt/Eq | 1.26 | Earnings | 2026/8/13 | SMA50 | -34.62% ($1.21) | Rel Volume | 0.21 | Prev Close | $0.78 |
| Employees | 92 | LT Debt/Eq | 1.18 | EPS/Sales Surpr. | 52.38% 26.35% | SMA200 | -23.57% ($1.03) | Avg Volume(3M) | 0.54M | Price | $0.79 |
| IPO | 2021/10/29 | Option/Short | No/Yes | Trades | 220 | Volume | 112,870 | Change | 1.04% |
☀️ A US-based dermatology-focused specialty pharmaceutical company at the commercial stage, selling the prescription drug Ameluz® for photodynamic therapy (PDT) along with its dedicated BF-RhodoLED® lamp. The company focuses on treating actinic keratosis, the pre-cancerous stage of skin cancer on exposed areas, and is currently pursuing FDA approval to expand indications to include the arms, legs, and trunk, as well as superficial basal cell carcinoma, based on recent clinical results.
Over the past 1 year, on the lower side
52% below its 1-year high.
Traded less than usual. That is 21% of its average volume.
BFRI has weak earning power
Of every $100 in sales, $2.97 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +62.5% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $25. Peers typically go for $196.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -79.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #72 of 83 in the industry
Based on market cap of $12M.
FAQ
What kind of company is BFRI?
BFRI belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BFRI?
The market cap of BFRI is approximately $12M, ranking 5,394 within its sector.
What is the 52-week high and low for BFRI?
BFRI has recorded a 52-week high of $1.66 and a low of $0.55.
